# BioCardia, Inc.

BioCardia, Inc. is an other based in Sunnyvale.

## Overview

- **Organization type:** other
- **Headquarters:** Sunnyvale
- **Assets under management:** Undisclosed
- **Website:** biocardia.com
- **LinkedIn:** https://www.linkedin.com/company/biocardia

## Regulatory record

- **Reports private funds:** No

## About

BioCardia is a publicly traded biotechnology company (NASDAQ: BCDA) developing cellular therapies for cardiovascular conditions. Founded with a focus on regenerative medicine, the company's lead candidates include CardiAMP autologous cell therapy for ischemic heart failure and the Morph DNA-guided catheter delivery system. The company's strategy centers on its proprietary cell delivery platform — the Morph catheter — which allows targeted intramyocardial injection. BioCardia has reported clinical trial data for CardiAMP in heart failure patients. Its pipeline also includes allogeneic cell therapy programs. As of 2026, BioCardia's market capitalization is modest, and the company has not disclosed significant family office investments or asset management operations. The firm is structured as a C-corporation, not a private investment vehicle. BioCardia's primary differentiator is its proprietary catheter technology paired with autologous cell therapy, a combination that targets a high unmet need in chronic heart failure. The company relies on capital markets and public equity, not private allocator capital.

## Sectors

- Biotech
- Cardiovascular
- Medical Devices

## Questions

### What does BioCardia do?

BioCardia develops cellular therapies for cardiovascular conditions, including its lead CardiAMP autologous cell therapy for ischemic heart failure and the Morph DNA-guided catheter platform for targeted delivery (per SEC filings). It is a publicly traded clinical-stage biotechnology company.

### What stage are BioCardia's therapies in?

BioCardia's therapies are in clinical development. The company has reported Phase III trial results for CardiAMP in heart failure. It has not received FDA approval for any commercial product.

### Who invests in BioCardia?

As a public company, BioCardia's investor base includes retail and institutional shareholders. No family office or allocator has disclosed a significant stake in the company per public filings.

### What is BioCardia's regulatory strategy?

BioCardia seeks FDA approval through clinical trials for its cell therapies. It has pursued both autologous and allogeneic approaches, with the goal of demonstrating safety and efficacy in heart failure patients.

### Does BioCardia have partnerships?

BioCardia has collaborated with academic medical centers and research institutions for clinical studies. It has not disclosed any significant commercial partnerships with large pharma or private equity firms.

---

Updated: 2026-07-11T01:49:53.000Z

Canonical page: https://altss.com/profile/biocardia-inc

Maintained by Altss — https://altss.com — methodology: https://altss.com/methodology